Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cuorips Inc. (4894.T)
Tokyo, JP
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based, and cell processing products. Furthermore, it offers contract development and manufacturing services, alongside expert consulting. The company, which was incorporated in 2017 and is based in Tokyo, Japan, previously operated under the name Cuore Inc. before adopting Cuorips Inc. in June 2017.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -12.42% | -14.73% | -21.99% | -51.20% | -14.20% | -11.58% | -12.70% | +319.21% | +319.21% | +319.21% | +319.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+21.2% ★ Q1'26: -96.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-54.7% Q1'26: -778.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-566.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-509.2% Q1'26: -6,102.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-124.4% Q1'26: -142.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.6% ★ Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
23.10M
est: 165.00M (-86.0%)
|
175.21M
est: 235.00M (-25.4%)
|
529.00M
529.00M – 529.00M
+125.1% YoY
|
| EBITDA |
-518.39M
est: -165.00M (-214.2%)
|
-513.57M
est: -235.00M (-118.5%)
|
-529.00M
-529.00M – -529.00M
-125.1% YoY
|
| EBIT |
-588.49M
est: -165.00M (-256.7%)
|
-590.26M
est: -235.00M (-151.2%)
|
-529.00M
-529.00M – -529.00M
-125.1% YoY
|
| Net Income |
-632.18M
est: -1.14B (+44.6%)
|
-644.34M
est: -2.01B (+67.9%)
|
-1.60B
-1.60B – -1.60B
+20.3% YoY
|
| SGA |
318.24M
est: 21.60B (-98.5%)
|
347.69M
est: 2.08B (-83.2%)
|
4.67B
4.67B – 4.67B
+125.1% YoY
|
| EPS |
-85.87
est: -142.50 (+39.7%)
|
-80.52
est: -244.50 (+67.1%)
|
-194.80
-194.80 – -194.80
+20.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 71.5K | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kazuyoshi Hirao | Chief Business Officer & Director | — | — |
| Tadayuki Tanimura | Executive Vice President & Director | — | — |
| Taichi Kobayashi | Chief Financial Officer | — | — |
| Takayuki Kusanagi | Chairman of the Board of Directors, President & Chief Executive Officer | — | — |
| Yoshiki Sawa | Chief Technology Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4894.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
